16.50Open16.50Pre Close0 Volume0 Open Interest57.50Strike Price0.00Turnover145.16%IV-10.81%PremiumJan 17, 2025Expiry Date20.50Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8428Delta0.0180Gamma1.73Leverage Ratio-0.0642Theta-0.0254Rho-1.46Eff Leverage0.0227Vega
Tandem Diabetes Care Stock Discussion
-- Worldwide GAAP sales increased 13 percent to $221.9 million compared to
second quarter 2023; worldwide non-GAAP sales(1) increased 12 percent to
$221.8 million compared to second quarter 2023.
-- More than 20,000 pumps shipped in the United States, a sequential
increase of 33 percent compared to first quarter 2024.
-- Launched Tandem Mobi with Dexcom G7 continuous glucose monitoring (CGM)
sensor integration in th...
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
As GLP-1 diet drug companies have grown in influence, they have grown to be the new leaders of the stock market.
$Novo-Nordisk A/S (NVO.US)$ , with Wegovy and Ozempic in hand, is now Europe's largest company with a market capitalization of $433 billion, and the Danish drug giant's rapid growth has even had a direct impact on the Danish krone exchange rate and interest rates.
Meanwhile, $Eli Lilly and Co (LLY.US)$ , whic...
No comment yet